Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM versus LOMANATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM versus LOMANATE.
IMODIUM vs LOMANATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a peripheral mu-opioid receptor agonist that inhibits peristalsis and prolongs transit time by reducing smooth muscle motility in the gastrointestinal tract. It also increases anal sphincter tone and decreases secretion, leading to reduced stool frequency and increased consistency.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
4 mg orally initially, followed by 2 mg after each unformed stool, not exceeding 16 mg/day. For chronic diarrhea: 4-8 mg/day in divided doses. Max 16 mg/day.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 10.8 h). In patients with hepatic impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Primarily fecal (90-95% as unchanged drug and glucuronide conjugates), renal (<2% unchanged, ~10% as metabolites). Biliary excretion is the major route for conjugated metabolites.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Category C
Category C
Antidiarrheal
Antidiarrheal